Michael Roberts ^UDM

Michael Roberts, Co-Founder and CEO at GenomeKey, leads the charge in enabling targeted sepsis treatment within hours rather than days. GenomeKey employs cutting-edge machine learning and DNA sequencing to drastically reduce the time it takes for doctors to determine the appropriate antibiotic for sepsis treatment. This innovation is crucial, as sepsis, a condition that can be fatal within hours, currently surpasses cancer in its impact. By providing an affordable test that delivers rapid results for every patient, GenomeKey's approach not only saves lives but also contributes to preserving antibiotics for critical situations.